Biosimilars – Levine Media Group

Bio Usawa Announced an Agreement With Pacific Environmental Technologies to Design, Build, and Deploy State-of-the-Art, Modular Biomanufacturing Units

Bio Usawa, Inc., a biopharmaceutical company based in San Francisco, Kigali, and Nairobi, committed to expanding access to life-saving biologics in Africa and underserved regions, today announced an agreement with Pacific Environmental Technologies, Inc., a global leader in cleanroom facility design and construction, to design, build, and deploy state-of-the-art, self-contained modular biomanufacturing units. Read here.

Bio Usawa Appoints Dr. Patrick Lukulay as Chief Operating Officer

SAN FRANCISCO and KIGALI, Rwanda, Feb. 26, 2025 (GLOBE NEWSWIRE) — Bio Usawa, Inc., a pioneering biotechnology company dedicated to developing high-quality, affordable monoclonal antibodies in Africa, appointed Dr. Patrick Lukulay as its Chief Operating Officer. Read here.

Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy

SAN FRANCISCO and KIGALI, Rwanda, Dec. 17, 2024 (GLOBE NEWSWIRE) — Bio Usawa, Inc., a leading biotechnology company committed to delivering affordable and accessible monoclonal antibody-based therapies for cancer, ophthalmic, autoimmune, and infectious diseases in Africa, has named Mr. Eric Karikari-Boateng its Head of Global Regulatory Strategy. Read here.

Bio Usawa and Rwandan Government Sign a Memorandum of Understanding to Manufacture Affordable Biologics in Africa

SAN FRANCISCO and KIGALI, Rwanda, Nov. 21, 2024 (GLOBE NEWSWIRE) — Bio Usawa and the Rwanda Development Board have partnered to establish Rwanda’s first manufacturing plant for affordable treatments for serious eye diseases like diabetic macular edema. Read here.